LB Pharmaceuticals IncLBRX stock score: 41/100

$40.04 · -0.05% · Scored Nov 19, 2026

Technical
54
Fundamental
37
News
51

The reading

LB Pharmaceuticals (LBRX) scores 41 out of 100, which reads weak, higher than 26% of Healthcare stocks and 24% of the 4,118 US stocks we score.

The composite weights fundamentals 80% and technicals 20%: fundamentals read 37, technicals 54.

Among the fundamentals, Quick Ratio at 100 and Price Target at 100 score highest, while Earnings Quality (Quarterly) at 0 weighs the most against it.

On the daily chart, trend-following indicators average 52 and contrarian oscillators 51.

News sentiment is neutral at 51; it is shown, not counted in the composite.

Since Aug 23, 2026 the composite has ranged from 39 to 57, and it is down 15 points over the period.

About LB Pharmaceuticals

LB Pharmaceuticals (LBRX) is a clinical-stage biopharmaceutical company developing new treatments for schizophrenia and other neuropsychiatric disorders. Its lead candidate, LB-102, is a once-daily oral drug from the benzamide class, related to amisulpride, an antipsychotic used outside the United States that has not been approved here for psychiatric use. LB-102 is designed to block dopamine and serotonin receptors involved in psychosis, and in a mid-stage trial it reduced schizophrenia symptoms compared with placebo, with results published in a major psychiatry journal. The company is running a pivotal late-stage trial in adults with acute schizophrenia and plans to study LB-102 in major depressive disorder as an add-on therapy, as well as in negative symptoms of schizophrenia and psychosis related to Alzheimer’s disease. LB Pharmaceuticals has no product revenue and funds research with cash raised from investors.

In schizophrenia, LB Pharmaceuticals would compete with established antipsychotics from Johnson & Johnson, AbbVie, Otsuka and Lundbeck, as well as Bristol Myers Squibb’s Cobenfy and many generic drugs. Its edge rests on a drug class with a long record of use in other countries, potential benefits on cognition and a possible first U.S. approval for a benzamide antipsychotic. Investors who follow LBRX stock tend to watch enrollment and topline results from the pivotal schizophrenia trial. Safety and tolerability findings are closely followed. Plans for depression and other indications, partnering and cash runway are other factors.

What’s driving the score

The strongest and weakest of the scorers that count toward LBRX’s composite. Each returns 0–100, higher is more bullish — including metrics where low is good, like P/E.

Fundamental

37

Pulling it up

  • Quick ratio measures a company's ability to meet short-term obligations with liquid assets.

  • Price target score compares the current stock price to analyst consensus targets.

  • Current assets divided by current liabilities: the ability to pay short-term bills.

Holding it back

26 weighted scorers; 13 had no data today and are left out rather than counted as zero.

Technical · daily

55

Pulling it up

Holding it back

  • Parabolic SAR (Stop and Reverse) provides trailing stop levels that follow price trends.

  • Simple Moving Average (10-period) smooths price action over 10 periods.

  • SPY SMA 20 measures the S&P 500 (SPY) position relative to its 20-period moving average.

62 weighted scorers; 3 had no data today and are left out rather than counted as zero.

News · shown, not counted

Global News
51

Technical score by timeframe

ChartScoreWeight
Hourly471
Daily553
Weekly562

Composite score, last 90 days

05010041Aug 23, 2026Nov 19, 2026Aug 23, 2026: 56Aug 24, 2026: 56Aug 25, 2026: 57Aug 26, 2026: 56Aug 27, 2026: 56Aug 28, 2026: 55Aug 29, 2026: 55Aug 30, 2026: 56Aug 31, 2026: 55Sep 1, 2026: 56Sep 2, 2026: 57Sep 4, 2026: 55Sep 5, 2026: 57Sep 6, 2026: 57Sep 7, 2026: 57Sep 8, 2026: 57Sep 9, 2026: 54Sep 10, 2026: 53Sep 11, 2026: 53Sep 12, 2026: 53Sep 13, 2026: 53Sep 14, 2026: 53Sep 15, 2026: 53Sep 16, 2026: 52Sep 17, 2026: 52Sep 18, 2026: 52Sep 19, 2026: 53Sep 20, 2026: 53Sep 21, 2026: 54Sep 22, 2026: 53Sep 23, 2026: 53Sep 24, 2026: 51Sep 25, 2026: 50Sep 26, 2026: 50Sep 27, 2026: 50Sep 28, 2026: 51Sep 29, 2026: 49Sep 30, 2026: 51Oct 1, 2026: 50Oct 2, 2026: 49Oct 3, 2026: 49Oct 4, 2026: 49Oct 5, 2026: 47Oct 6, 2026: 47Oct 7, 2026: 48Oct 8, 2026: 48Oct 9, 2026: 51Oct 10, 2026: 51Oct 11, 2026: 51Oct 12, 2026: 50Oct 13, 2026: 49Oct 14, 2026: 48Oct 15, 2026: 50Oct 16, 2026: 51Oct 17, 2026: 51Oct 18, 2026: 51Oct 19, 2026: 52Oct 20, 2026: 54Oct 21, 2026: 52Oct 22, 2026: 53Oct 23, 2026: 51Oct 24, 2026: 51Oct 25, 2026: 51Oct 26, 2026: 52Oct 27, 2026: 52Oct 29, 2026: 52Oct 30, 2026: 53Nov 1, 2026: 53Nov 2, 2026: 51Nov 3, 2026: 54Nov 4, 2026: 54Nov 5, 2026: 50Nov 6, 2026: 53Nov 7, 2026: 53Nov 10, 2026: 54Nov 11, 2026: 55Nov 12, 2026: 39Nov 13, 2026: 42Nov 14, 2026: 42Nov 15, 2026: 42Nov 17, 2026: 40Nov 18, 2026: 41Nov 19, 2026: 41
Show the daily numbers
DateComposite
Nov 19, 202641
Nov 18, 202641
Nov 17, 202640
Nov 15, 202642
Nov 14, 202642
Nov 13, 202642
Nov 12, 202639
Nov 11, 202655
Nov 10, 202654
Nov 7, 202653
Nov 6, 202653
Nov 5, 202650
Nov 4, 202654
Nov 3, 202654
Nov 2, 202651
Nov 1, 202653
Oct 30, 202653
Oct 29, 202652
Oct 27, 202652
Oct 26, 202652
Oct 25, 202651
Oct 24, 202651
Oct 23, 202651
Oct 22, 202653
Oct 21, 202652
Oct 20, 202654
Oct 19, 202652
Oct 18, 202651
Oct 17, 202651
Oct 16, 202651
Oct 15, 202650
Oct 14, 202648
Oct 13, 202649
Oct 12, 202650
Oct 11, 202651
Oct 10, 202651
Oct 9, 202651
Oct 8, 202648
Oct 7, 202648
Oct 6, 202647
Oct 5, 202647
Oct 4, 202649
Oct 3, 202649
Oct 2, 202649
Oct 1, 202650
Sep 30, 202651
Sep 29, 202649
Sep 28, 202651
Sep 27, 202650
Sep 26, 202650
Sep 25, 202650
Sep 24, 202651
Sep 23, 202653
Sep 22, 202653
Sep 21, 202654
Sep 20, 202653
Sep 19, 202653
Sep 18, 202652
Sep 17, 202652
Sep 16, 202652
Sep 15, 202653
Sep 14, 202653
Sep 13, 202653
Sep 12, 202653
Sep 11, 202653
Sep 10, 202653
Sep 9, 202654
Sep 8, 202657
Sep 7, 202657
Sep 6, 202657
Sep 5, 202657
Sep 4, 202655
Sep 2, 202657
Sep 1, 202656
Aug 31, 202655
Aug 30, 202656
Aug 29, 202655
Aug 28, 202655
Aug 27, 202656
Aug 26, 202656
Aug 25, 202657
Aug 24, 202656
Aug 23, 202656

Key facts

Market cap
$1.3B
Sector
Healthcare
Industry
Biotechnology
Beta
—
Risk grade (1–10)
8
Next earnings
Nov 12, 2026

Questions

What is LBRX's stock rating today?

LBRX scores 41/100 (Weak) as of Nov 19, 2026: technical 54, fundamental 37, and news sentiment 51, which is shown but not counted. Scores are recomputed every night.

What does LB Pharmaceuticals do?

LB Pharmaceuticals (LBRX) is a clinical-stage biopharmaceutical company developing new treatments for schizophrenia and other neuropsychiatric disorders. Its lead candidate, LB-102, is a once-daily oral drug from the benzamide class, related to amisulpride, an antipsychotic used outside the United States that has not been approved here for psychiatric use.

Is LBRX stock a buy?

The score is not a buy or sell recommendation. A 41 says the technical and fundamental signals we measure lean weak today, relative to every other stock scored the same way. Use the breakdown above to see why, and treat it as a starting point for your own research.

How is the LBRX score calculated?

88 weighted scorers feed it today: 26 fundamental, scored against Healthcare ranges, and 62 technical on the daily chart, with 3 timeframes blended into the technical total. Every scorer returns 0–100; missing data is left out, never counted as zero.

Scores are information, not investment advice. Computed from Yahoo Finance, Finnhub and Alpha Vantage data; technical indicators via TA-Lib. Past scores do not predict future returns.

Embed this score

A badge for a blog post, newsletter or README. It updates every night and links back here. More badges

LBRX stock score

HTML

<a href="https://stocksscores.com/stocks/lbrx/"><img src="https://stocksscores.com/stocks/lbrx/badge.svg" alt="LBRX stock score" height="20"></a>

Markdown

[![LBRX stock score](https://stocksscores.com/stocks/lbrx/badge.svg)](https://stocksscores.com/stocks/lbrx/)